GENTAMICIN SULFATE

Search structure
Trade Names:
Synonyms:
Status: Approved (1970)
Entry Type: Small molecule
Molecule Category: Salt
UNII: 8X7386QRLV
Parent Compound: GENTAMICIN

Structure
InChI Key RDEIXVOBVLKYNT-VQBXQJRRSA-N
Smile CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.O=S(=O)(O)O
InChI
InChI=1S/C21H43N5O7.C20H41N5O7.C19H39N5O7.H2O4S/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20;1-8(21)12-5-4-9(22)18(30-12)31-15-10(23)6-11(24)16(13(15)26)32-19-14(27)17(25-3)20(2,28)7-29-19;1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17;1-5(2,3)4/h9-20,25-29H,5-8,22-24H2,1-4H3;8-19,25-28H,4-7,21-24H2,1-3H3;8-18,24-27H,3-7,20-23H2,1-2H3;(H2,1,2,3,4)/t9?,10-,11+,12-,13+,14+,15-,16-,17+,18-,19-,20-,21+;8?,9-,10+,11-,12+,13+,14-,15-,16+,17-,18-,19-,20+;8-,9+,10-,11+,12-,13+,14+,15-,16+,17+,18+,19-;/m110./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C60H125N15O25S
Molecular Weight 1488.81
AlogP None
Hydrogen Bond Acceptor None
Hydrogen Bond Donor None
Number of Rotational Bond None
Polar Surface Area None
Molecular species None
Aromatic Rings None
Heavy Atoms None

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Bacterial 70S ribosome inhibitor ISBN
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 104
Unclassified protein
- 26000 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Gonorrhea 3 D006069 ClinicalTrials
Pneumonia 3 D011014 ClinicalTrials
Abdominal Abscess 2 D018784 ClinicalTrials
Pneumonia, Bacterial 2 D018410 ClinicalTrials
Leishmaniasis 2 D007896 ClinicalTrials
Hypotrichosis 2 D007039 ClinicalTrials
Epidermolysis Bullosa 1 D004820 ClinicalTrials
Epidermolysis Bullosa Dystrophica 1 D016108 ClinicalTrials
Epidermolysis Bullosa, Junctional 1 D016109 ClinicalTrials
Osteomyelitis 0 D010019 ClinicalTrials

Related Entries

Scaffolds

Parent
Mixture

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
11.02
Immune system disorders
10.68
Nervous system disorders
9.9
Injury, poisoning and procedural complications
8.16
Vascular disorders
8.09
Infections and infestations
6.84
Skin and subcutaneous tissue disorders
5.61
Eye disorders
5.0
Gastrointestinal disorders
4.9
Renal and urinary disorders
4.82
Ear and labyrinth disorders
3.87
Investigations
3.81
Cardiac disorders
3.42
Respiratory, thoracic and mediastinal disorders
2.86
Metabolism and nutrition disorders
2.62

Cross References

Resources Reference
ChEMBL CHEMBL3039594
FDA SRS 8X7386QRLV
CONTENTS